News & Events

What EGFR and KRAS G12C Results Tell Clinicians Beyond Treatment Selection

What EGFR and KRAS G12C Results Tell Clinicians Beyond Treatment Selection

How KRAS G12C Data Should Shape Combination Trial Design

How KRAS G12C Data Should Shape Combination Trial Design

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib for KRAS G12D-Mutated Lung Cancer

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib for KRAS G12D-Mutated Lung Cancer

What EGFR and KRAS G12C Results Tell Clinicians Beyond Treatment Selection

What EGFR and KRAS G12C Results Tell Clinicians Beyond Treatment Selection

Astellas moves KRAS G12D degrader setidegrasib into Phase III lung cancer trial

Astellas moves KRAS G12D degrader setidegrasib into Phase III lung cancer trial

Astellas Reports First Patient Dosing in P-III Study of Setidegrasib in Previously Treated KRAS G12D-Mutated NSCLC

Astellas Reports First Patient Dosing in P-III Study of Setidegrasib in Previously Treated KRAS G12D-Mutated NSCLC

Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D- Mutated Advanced Non-Small Cell Lung Cancer

Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D- Mutated Advanced Non-Small Cell Lung Cancer